The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly
recognised, not only in infants, but also in older adults (aged≥ 65 years). Advances in …

Respiratory syncytial virus (RSV) is responsible for a significant proportion of global
morbidity and mortality affecting young children and older adults. In the aftermath of formalin …

Despite of the rapid development of the vaccines against the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), it will take several months to have enough doses …

Trained immunity is a type of non-specific memory-like immune response induced by some
pathogens and vaccines, such as BCG, which can confer antigen-independent protection …

Evidence has increasingly shown that the lungs are a major site of immune regulation. A
robust and highly regulated immune response in the lung protects the host from pathogen …

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract viral disease
in infants and young children. Presently, there are no explicit recommendations for RSV …

The manufacture of pharmaceutical products made under good manufacturing practices
(GMP) must comply with the guidelines of national regulatory bodies based on international …

Background Respiratory syncytial virus (RSV) is responsible for most respiratory tract
infections and hospitalizations in infants and represents a significant economic burden for …

Respiratory Syncytial Virus (RSV) poses a significant global health concern as a major
cause of lower respiratory tract infections (LRTIs). Over the last few years, substantial efforts …

Respiratory syncytial virus (RSV) is the major cause of respiratory illness in infants
worldwide. Neurologic alterations, such as seizures and ataxia, have been associated with …